Study limitation: This is a phase 2 trial conducted exclusively in Italy; results may not generalize to other populations or healthcare settings | ReachRx
SBRT plus abiraterone acetate and ADT versus abiraterone acetate and ADT in oligometastatic castrate-resistant prostate cancer (ARTO): long-term, unplanned overall survival analysis of an open-label, randomised, phase 2 trial
Study limitation reported by the research below: “This is a phase 2 trial conducted exclusively in Italy; results may not generalize to other populations or healthcare settings.”
